1261566-52-2

Usage

Uses

Used in Pharmaceutical Industry:
(3-amino-5-methoxyphenyl)methanol is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential biological activities. Its presence in the molecule allows for the development of new drugs with anti-inflammatory and antioxidant properties, which can be beneficial in treating various diseases and conditions.
Used in Medicinal Applications:
(3-amino-5-methoxyphenyl)methanol is used as a therapeutic agent for its potential anti-inflammatory and antioxidant effects. (3-amino-5-methoxyphenyl)methanol's unique structure enables it to modulate biological pathways and target specific cellular processes, making it a promising candidate for the treatment of various inflammatory and oxidative stress-related disorders.
Used in Materials Science:
(3-amino-5-methoxyphenyl)methanol is used as a building block in the development of new materials with specific properties. Its versatile structure allows for the creation of novel materials with potential applications in various industries, such as electronics, coatings, and adhesives.

Upstream product

• 74165-74-5 3-amino-5-methoxybenzoic acid 
• 217314-47-1 methyl 3-amino-5-methoxybenzoate 

Downstream Products

• 1407159-67-4 toluene-4-sulfonic acid 3-azido-5-methoxybenzyl ester 
• 1407159-68-5 7-[4-(3-azido-5-methoxybenzyloxy)phenylcarbamoyl]heptanoic acid methyl ester 
• 1417539-99-1 7-[4-(3-azido-5-methoxybenzyloxy)phenylcarbamoyl]heptanoic acid 
• 1407159-62-9 C₂₄H₂₉N₇O₅ 
• 1407159-63-0 C₃₀H₃₃N₇O₅ 
• 1346245-89-3 C₂₄H₂₈N₆O 
• 1346245-88-2 C₂₀H₁₇N₅O₂ 

Relevant academic research and scientific papers

Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors

3-Acyl-indole derivative 1 was identified as a novel dengue virus (DENV) inhibitor from a DENV serotype 2 (DENV-2) phenotypic antiviral screen. Extensive SAR studies led to the discovery of new derivatives with improved DENV-2 potency as well as activity in nanomolar to micromolar range against the other DENV serotypes. In addition to the potency, physicochemical properties and metabolic stability in rat and human microsomes were improved during the optimization process. Chiral separation of the racemic mixtures showed a clear preference for one of the two enantiomers. Furthermore, rat pharmacokinetics of two compounds will be discussed in more detail, demonstrating the potential of this new series of pan-serotype-DENV inhibitors.

Novel histone deacetylase 8 ligands without a zinc chelating group: Exploring an 'upside-down' binding pose

A novel series of HDAC8 inhibitors without a zinc-chelating hydroxamic acid moiety is reported. Photoaffinity labeling and molecular modeling studies suggest that these ligands are likely to bind in an 'upside-down' fashion in a secondary binding site pro

PYRAZOLYL QUINAZOLINE KINASE INHIBITORS

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.